Business Context and Reporting Period
Company: Processa Pharmaceuticals, Inc. (PCSA)
Filing Type: Form 8-K (Current Report)
Date of Report: January 27, 2025 (Event Date)
Reporting Period: The filing covers a capital raise event closed on January 29, 2025.
Key Financial Metrics
This filing details a registered public offering rather than periodic financial performance. Key capital metrics include:
- Gross Proceeds: Approximately $5.0 million (excluding potential proceeds from warrant exercises).
- Securities Issued:
- 1,030,972 shares of Common Stock.
- 8,050,672 Series A Warrants (Exercise Price: $0.65; Expiry: 5 years).
- 4,025,336 Series B Warrants (Exercise Price: $0.65; Expiry: 18 months).
- 7,019,700 Pre-Funded Warrants.
- Offering Price: $0.615 per share (combined with warrants) for institutional investors; $0.7975 for the CEO and certain board members.
- Transaction Costs: Placement agent fee of 6.5% of gross proceeds (4.0% for issuer-directed investors), plus up to $20,000 expense allowance and up to $75,000 legal fee reimbursement.
Note: The filing does not provide data on revenue, profit, operating cash flow, margins, or existing debt levels.
Material Changes
The primary material change is the entry into a Material Definitive Agreement (Securities Purchase Agreement) and the subsequent closing of the Offering. This transaction significantly increases the company's cash liquidity and expands its capital structure through the issuance of new equity and warrants. The filing does not provide comparative financial data to quantify changes in revenue or profitability versus prior periods.
Outlook, Risks, and Management Commentary
- Use of Proceeds: The Company anticipates using net proceeds for general corporate purposes.
- Lock-Up Provisions: The Company agreed not to issue additional common stock or equivalents for 60 days post-closing. Additionally, the Company is restricted from "at-the-market" offerings for 6 months, with an exception for an existing ATM facility with the placement agent after the 60-day period.
- Regulatory Status: Securities were sold pursuant to a Registration Statement on Form S-1 declared effective on January 27, 2025.
- Management Participation: The CEO, certain board members, and existing institutional investors participated in the Offering.
Investor Verification Checklist
- Verify the final net proceeds after deducting the 6.5% placement fee and legal expenses.
- Review the dilution impact of the 1,030,972 new shares and the 12,076,008 total warrants issued.
- Confirm the terms of the Pre-Funded Warrants and their conversion mechanics.
- Monitor the 60-day and 6-month lock-up periods regarding future equity issuances.
- Check subsequent filings for the specific allocation of the $5.0 million in proceeds.